Clinical trial
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With…
NCT00461773 · Yale University, Other · Terminated
Key facts
| NCT number | NCT00461773 |
|---|---|
| Title | Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer |
| Official title | Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer |
| Lead sponsor | Yale University, Other |
| Collaborators | Novartis Industry Genentech, Inc. |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hormone-Sensitive Breast Cancer, Breast Cancer |
| Intervention type | Drug |
| Interventions | Letrozole, Bevacizumab |
| Enrollment | 5 |
| Start date | Mar 1, 2007 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Apr 18, 2007 |
| Last update posted | Mar 16, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: